Literature DB >> 7597674

Bilateral sequential lung transplantation for end stage septic lung disease.

A Hasan1, P A Corris, M Healy, N Wrightson, A D Gascoigne, D A Waller, I Wilson, C J Hilton, F K Gould, J Forty.   

Abstract

BACKGROUND: Bilateral sequential lung transplantation (BSLT) has been widely adopted as an alternative to combined heart and lung transplantation for the management of end stage septic lung disease in many transplant centres.
METHODS: A retrospective review was undertaken of the first 32 consecutive patients with septic lung disease to undergo BSLT at the Freeman Hospital.
RESULTS: Between April 1988 and October 1994 32 patients underwent BSLT. Survival at 30 days was 85% and actuarial survival at one year was 70%. Improved pulmonary function was seen in all surviving patients.
CONCLUSION: BSLT for septic lung disease offers comparable survival to heart-lung transplantation, with excellent functional results. Long term results may be superior because the disadvantages of transplanting the heart are avoided.

Entities:  

Mesh:

Year:  1995        PMID: 7597674      PMCID: PMC1021232          DOI: 10.1136/thx.50.5.565

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  12 in total

1.  Successful heart-lung transplantation for cystic fibrosis.

Authors:  K Jones; T Higenbottam; J Wallwork
Journal:  Chest       Date:  1988-03       Impact factor: 9.410

2.  Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease.

Authors:  B A Reitz; J L Wallwork; S A Hunt; J L Pennock; M E Billingham; P E Oyer; E B Stinson; N E Shumway
Journal:  N Engl J Med       Date:  1982-03-11       Impact factor: 91.245

3.  Double-lung transplantation for cystic fibrosis. The Cystic Fibrosis Transplant Study Group.

Authors:  H Shennib; M Noirclerc; P Ernst; D Metras; D S Mulder; R Giudicelli; F Lebel; J F Dumon
Journal:  Ann Thorac Surg       Date:  1992-07       Impact factor: 4.330

4.  Improved technique for bilateral lung transplantation: rationale and initial clinical experience.

Authors:  M K Pasque; J D Cooper; L R Kaiser; D A Haydock; A Triantafillou; E P Trulock
Journal:  Ann Thorac Surg       Date:  1990-05       Impact factor: 4.330

5.  Lung immunogenicity, rejection, and obliterative bronchiolitis.

Authors:  C M Burke; A R Glanville; J Theodore; E D Robin
Journal:  Chest       Date:  1987-09       Impact factor: 9.410

6.  Risk factors for survival following combined heart-lung transplantation. The first 100 patients.

Authors:  L D Sharples; J P Scott; C Dennis; T W Higenbottam; S Stewart; T Wreghitt; S R Large; F C Wells; J Wallwork
Journal:  Transplantation       Date:  1994-01       Impact factor: 4.939

7.  Single lung transplantation with simultaneous contralateral pneumonectomy for cystic fibrosis.

Authors:  J Forty; A Hasan; F K Gould; P A Corris; J H Dark
Journal:  J Heart Lung Transplant       Date:  1994 Jul-Aug       Impact factor: 10.247

8.  Redo lung transplantation: a North American-European experience.

Authors:  R J Novick; M P Kaye; G A Patterson; B Andréassian; W Klepetko; A H Menkis; F N McKenzie
Journal:  J Heart Lung Transplant       Date:  1993 Jan-Feb       Impact factor: 10.247

9.  Bronchial circulation after experimental lung transplantation. The effect of long-term administration of prednisolone.

Authors:  K Inui; H J Schäfers; M Aoki; V Becker; B Ongsiek; J Kemnitz; A Haverich; H G Borst
Journal:  J Thorac Cardiovasc Surg       Date:  1993-03       Impact factor: 5.209

10.  Long-term results, hemodynamics, and complications after combined heart and lung transplantation.

Authors:  K D Dawkins; S W Jamieson; S A Hunt; J C Baldwin; C M Burke; A Morris; M E Billingham; J Theodore; P E Oyer; E B Stinson
Journal:  Circulation       Date:  1985-05       Impact factor: 29.690

View more
  3 in total

1.  Risk factors and costs associated with an asthma attack.

Authors:  G Hoskins; C McCowan; R G Neville; G E Thomas; B Smith; S Silverman
Journal:  Thorax       Date:  2000-01       Impact factor: 9.139

2.  Preliminary findings of quorum signal molecules in clinically stable lung allograft recipients.

Authors:  C Ward; M Cámara; I Forrest; R Rutherford; G Pritchard; M Daykin; A Hardman; A de Soyza; A J Fisher; P Williams; P A Corris
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

3.  Prevalence and clonality of Burkholderia cepacia complex genomovars in UK patients with cystic fibrosis referred for lung transplantation.

Authors:  A De Soyza; K Morris; A McDowell; C Doherty; L Archer; J Perry; J R W Govan; P A Corris; K Gould
Journal:  Thorax       Date:  2004-06       Impact factor: 9.139

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.